XTAI
3054
Market cap159mUSD
Jul 09, Last price
63.40TWD
1D
3.59%
1Q
-15.69%
Jan 2017
119.20%
IPO
-71.69%
Name
LIWANLI Innovation Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
LIWANLI Innovation Co., Ltd. operates within the biomedical science sector, concentrating on the development and distribution of nutrition and healthcare solutions. The company's diverse product portfolio, which notably features the Vigoway line and various powdered formulations, is designed to serve a wide range of consumers, including men, women, seniors, and children. Its extensive offerings encompass products such as probiotic enzymes, active nutrients, resveratrol red grape extract, and a variety of soft gels (including those with algae DHA, shea butter with type II collagen, and algae astaxanthin Q10). Other specialized items include cordyceps militaris powder, tooth guard tablets, bovine and goat's milk bites, bilberry tablets, and DHA and vitamin D3 drops, among others. The firm was formerly known as Carry Technology International Co., Ltd. before officially adopting its current name, LIWANLI Innovation Co., Ltd., in 2015. Established in 1980, the company's headquarters are located in New Taipei City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||